Patients with NDD CKD receiving recombinant human erythropoietin (rHuEPO), darbepoetin alfa (DA), or epoetin beta pegol (EBP) were randomized or allocated to DA or roxadustat in a phase 3, multicenter, partially randomized, open-label study (1517-CL-0310) [12]. The gene discussed is EPO; the disease is chronic kidney disease.